Volume 4, Number 1—March 1998
Proteases of Malaria Parasites: New Targets for Chemotherapy
|Chloroquine||TX of and CP against non- Pf and sensitive Pf parasites||Very safe; low cost; long half-life||Widespread R|
|Quinine/quinidine||Best TX for Pf malaria; low cost||Limited R; rapidly acting||Fairly toxic (cinchonism, cardiac)|
|Amodiaquineb||TX of R Pf malaria||Low cost||Toxicity (bone marrow, liver); R common|
|Mefloquine||CP against R Pf malaria; not approved for TX in United States||Relatively little R, though increasing; long half-life||Moderately toxic (mostly CNS); high cost; R in SE Asia|
|Fansidar||TX of Pf malaria; no longer recommended for CP||Relatively low cost; long half-life||Skin toxicity (can be fatal); increasing R|
|Primaquine||Eradication of chronic liver stage Pv, Po malaria||Only drug for this indication||Hemolysis with G6PD deficiency; increasing R|
|Proguanilb||CP only (often with chloroquine)||Low cost; nontoxic||R common|
|Maloprimb||CP only (often with chloroquine)||Low cost||R common; skin rashes|
|Tetracyclines||CP; TX of Pf malaria in combination with quinine||Low cost||Skin and gastrointestinal toxicity|
aTX, therapy; CP, chemoprophylaxis; R, resistance/resistant; Pf, Plasmodium falciparum; Pv, P. vivax; Po, P. ovale; CNS, central nervous system; G6PD, glucose 6-phosphate dehydrogenase.
bNot available in the United States.